Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash and cash equivalents of $125.9 million. We have incurred net losses and negative cash flows from operations since inception. We expect to continue to incur operating losses and negative operating cash flows for the foreseeable future and as a result, there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Kodiak Sciences established an automatic shelf registration for common stock, preferred stock, debt securities, warrants and units, and a $350,000,000 common stock distribution agreement with J.P. Morgan dated October 20, 2026.
Kodiak Sciences Inc. said Zenkuda and tabirafusp-ted met primary endpoints in the Phase 3 DAYBREAK wet AMD study, with 54% of Zenkuda patients achieving 6-month durability at year one. Kodiak plans a Zenkuda three-indication BLA in 4Q2026.
